OMNICARE, INC. for OMNICARE INC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part D reimbursement; Medicare Part D audit policy; Medicare anti-fraud, waste and abuse policy; Medicaid FFS drug reimbursement; Medicare innovative health care and delivery models; Post-acute care payment policy reform; Medicare Part D network access issues; Safe-harbor and anti-kickback policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH TERRY | — |
Pharmacy PHA
Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities; Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs; Controlled substances policy; Biosimilars policy; Hazardous drug handling policy; FDA drug compounding policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH TERRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.